WEBULL
WebtradeDownload

Does Haleon (LSE:HLN) Trade Below Fair Value After Its Selloff?

Simply Wall St · 1d ago

Haleon has just seen its share price fall sharply, and that slide has put a spotlight on a simple question for investors who care about cash flows. Is the current market price still a fair reflection of what the business can earn and distribute over time, or has sentiment moved faster than the underlying numbers justify?

  • The stock has fallen about 9.7% over the past week, which puts recent cash flow expectations under closer scrutiny as investors reassess what they are willing to pay.
  • A new £500 million share buyback programme, together with reduced growth expectations and regulatory setbacks, can reshape future cash flow allocation between reinvestment and returning money to shareholders.
  • What if you looked at Haleon through its earnings instead? See what Haleon's 18.3x P/E says about the price.

The issue now is whether Haleon's current share price is supported by the cash flows implied in its intrinsic value estimate using the Discounted Cash Flow (DCF) approach.

If you want to stress test whether Haleon's recent share price slide and cash flow questions line up with opportunities elsewhere, compare it with the companies in the 14 high quality undervalued stocks

Does Haleon Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model here focuses on the cash that Haleon can generate for shareholders over time. Latest twelve month free cash flow sits at about £2.48b, and the projections used in the model assume that this cash generation continues to grow rather than contract, although at a measured pace rather than aggressive expansion.

On those inputs, the DCF estimate comes out substantially above the current share price of £3.38. Because the new £500 million buyback redirects part of that cash towards repurchases instead of only reinvestment, the model effectively treats Haleon as a mature cash generator where steady free cash flow matters more than rapid revenue growth. The weakened growth outlook and China regulatory hit help explain why the market price has moved away from what the cash flows support. Find out what Haleon could be worth using our Discounted Cash Flow (DCF) estimate.

The Haleon Narrative: What Would Justify Today's Price?

Simply Wall St Narratives take that DCF puzzle around Haleon and spell out which paths for growth, margins and earnings would need to play out for the current share price to look significantly higher or lower over time. These Narratives are available on the platform's Community page. Where a single ratio or model offers one outcome, these scenarios lay out the future business conditions that outcome relies on so you can watch how closely reality tracks those assumptions.

Community views on Haleon are split between those who see the cash machine in oral health and cost savings and those who focus on slower group growth.

Bull case: 19% undervalued

"The main thing that has to go right is that Haleon turns its cost savings, AI driven efficiencies and local manufacturing investments in India and China into sustained profit growth while managing weaker respiratory seasons…"

Discover why this Narrative puts Haleon at 19% undervalued.

Bear case: 16% overvalued

"Although Haleon continues to talk up premium, clinically supported oral health launches that have historically outgrown the wider category, the group is still only delivering 2.6% organic revenue growth in the first half of 2026 against a 4% to 6% ambition…"

Explore why this Narrative puts Haleon at 16% overvalued.

Before acting on Haleon’s valuation, there is one more lever to examine

Who steers Haleon, how their incentives are structured and whether those rewards really track your interests can matter as much as any cash flow model. See who runs Haleon and how they are paid.